Single Nucleotide Polymorphism (SNP) genotyping Market to 2027, Future Outlook, COVID-19 Impact Analysis, Forecast 2021-2027

The global SNP genotyping market is expected to record a 21% CAGR over the forecast period. SNP analysis is widely used in a variety of fields of genetics and related research, and is commonly associated with studying the genetic determinants of many complex diseases. SNP technology is widely used for detection and is useful for the causes of several human diseases such as cancer, cardiovascular, Alzheimer’s and asthma.

A full report of Single Nucleotide Polymorphism (SNP) genotyping Market available at https://www.orionmarketreports.com/single-nucleotide-polymorphism-snp-genotyping-market/52678/

Key players in this market area are, Sequenom, Inc., Douglas Scientific LLC, PREMIER Biosoft, Sequenom Inc., Luminex Corp., Life Technologies Corp., Fluidigm, Illumina, Inc., Affymetrix, Inc.

Single Nucleotide Polymorphism (SNP) genotyping Market Segmentations

By Technology

• SNP Genechips and Microarrays
• TaqMan Assay (Allelle-Specific Hybridization)
• SNP genotyping based upon Pyrosequencing
• SN Plex based upon Applied Biosystems
• Sequenom Masarray MALDI-TOF
• RFLP (Restricted Fragment Length Polymorphism)
• SSCP (Single-Strand Conformation Polymorphism)
• ARMS (Amplication Refractory Mutation System)
• Other SNP genotyping technologies

By Application

• Animal genetics
• Plant improvement
• Diagnostic research
• Aquaculture
• Pharmaceuticals and Pharmacogenomics
• Agricultural Biotechnology
• Animal Livestock and breeding
• Other SNP applications

(This release has been published on OMR Industry Journal. OMR Industry Journal is not responsible for any content included in this release.)